Aptahem AB (publ) announce today that the company has signed an agreement with their collaboration partner LGC Group to initiate the GMP (Good Manufacturing Practice) manufacturing of Apta-1. [...]
Aptahem AB (publ) announce today that the company has received patent approval in India for patent family 1, with patent application number 6250/DELNP/2010. The patent, with the patent number [...]
BioStock published an article on 22 December 2020 about Aptahem, which can be read in full below. Aptahem, which is developing an emergency medicine for the treatment of sepsis, carried out an [...]
BioStock published an article on 8 December 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an emergency treatment [...]
BioStock published an article on 26 November 2020 about Aptahem, which can be read in full below. Biotechnology company Aptahem, that develops its drug candidate Apta-1 for the treatment of [...]
Aptahem AB (publ), announce today that the company enters a collaboration agreement with the German company Granzer Regulatory Consulting and Services to prepare for applications to the European [...]
BioStock published an article on 15 October 2020 about Aptahem, which can be read in full below. On September 25, Bert Junno was elected Chairman of the Board of the biotech company Aptahem. As a [...]
Aptahem AB (publ), announce today that the Chairman of the Board of Directors, Kjell G Stenberg, has requested his own resignation from the Board. Due to this, the Board of Directors will call [...]
Aptahem AB, a leading developer of aptamer-based drugs, announced today that the company is now starting large-scale manufacturing after LGC Bioresearch Technologies Inc. (LGC) completed the [...]
BioStock published an article on 10 July 2020 about Aptahem, which can be read in full below. Last night, Malmö-based Aptahem announced that they have entered a preclinical collaboration with the [...]
